JP2016521114A5 - - Google Patents

Download PDF

Info

Publication number
JP2016521114A5
JP2016521114A5 JP2015562041A JP2015562041A JP2016521114A5 JP 2016521114 A5 JP2016521114 A5 JP 2016521114A5 JP 2015562041 A JP2015562041 A JP 2015562041A JP 2015562041 A JP2015562041 A JP 2015562041A JP 2016521114 A5 JP2016521114 A5 JP 2016521114A5
Authority
JP
Japan
Prior art keywords
macrophages
polypeptide
differentiation
expression
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015562041A
Other languages
English (en)
Japanese (ja)
Other versions
JP6437467B2 (ja
JP2016521114A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/054441 external-priority patent/WO2014139883A1/en
Publication of JP2016521114A publication Critical patent/JP2016521114A/ja
Publication of JP2016521114A5 publication Critical patent/JP2016521114A5/ja
Application granted granted Critical
Publication of JP6437467B2 publication Critical patent/JP6437467B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015562041A 2013-03-14 2014-03-07 線維化疾患治療において有用な分子標的及び化合物、並びにこれらの同定方法 Active JP6437467B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361781220P 2013-03-14 2013-03-14
US61/781,220 2013-03-14
PCT/EP2014/054441 WO2014139883A1 (en) 2013-03-14 2014-03-07 Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases

Publications (3)

Publication Number Publication Date
JP2016521114A JP2016521114A (ja) 2016-07-21
JP2016521114A5 true JP2016521114A5 (enExample) 2017-04-06
JP6437467B2 JP6437467B2 (ja) 2018-12-19

Family

ID=50239627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562041A Active JP6437467B2 (ja) 2013-03-14 2014-03-07 線維化疾患治療において有用な分子標的及び化合物、並びにこれらの同定方法

Country Status (4)

Country Link
US (2) US20160054304A1 (enExample)
EP (1) EP2972322B1 (enExample)
JP (1) JP6437467B2 (enExample)
WO (1) WO2014139883A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018149978A1 (en) * 2017-02-16 2018-08-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. ALTERNATIVE ACTIVATION OF MACROPHAGES (M2 CELLS) THROUGH THE POLYAMINE-eIF5a-HYPUSINE AXIS
US11536723B2 (en) 2017-05-24 2022-12-27 Mayo Foundation For Medical Education And Research Integrated immunoassay
CN111601606A (zh) * 2017-11-29 2020-08-28 菲格内有限责任公司 用于活化的成纤维细胞与免疫细胞的相互作用及其用途
CA3110618A1 (en) * 2018-08-29 2020-03-05 Riptide Bioscience, Inc. Peptides having immunomodulatory properties
GB201900724D0 (en) * 2019-01-18 2019-03-06 King S College London Antibody
IL284066B2 (en) * 2019-08-01 2025-06-01 Illumina Inc Flow cells
CN114269945B (zh) 2019-08-23 2024-07-19 宝洁公司 鉴定纤维化过程的调节物的方法
WO2021141733A1 (en) 2020-01-07 2021-07-15 The Procter & Gamble Company Method of modulating a fibrotic condition
WO2022060466A1 (en) * 2020-09-21 2022-03-24 Massachusetts Institute Of Technology Compounds, targets and pathways for macrophage modulation
CN117959323B (zh) * 2024-01-12 2025-01-21 南方医科大学南方医院 环状rna在制备防治放射性肝纤维化的药物中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
GB9620749D0 (en) 1996-10-04 1996-11-20 Brax Genomics Ltd Identifying antisense oligonucleotides
WO1999001139A1 (en) 1997-07-03 1999-01-14 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
US6004753A (en) * 1997-12-01 1999-12-21 Incyte Pharmaceuticals, Inc. Human S1-5 ECMP-like protein
GB2335035B (en) 1998-03-03 2003-05-28 Brax Genomics Ltd Screening for functional antisense agents
US7332337B2 (en) 2000-05-16 2008-02-19 Galapagos Nv Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells
JP2004123539A (ja) * 2001-03-13 2004-04-22 Japan Tobacco Inc 新規ピラゾロピリジン化合物及び医薬用途
JP2004123537A (ja) * 2000-06-20 2004-04-22 Japan Tobacco Inc ピラゾロピリジン化合物及びその医薬用途
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
JP2005300158A (ja) * 2001-03-26 2005-10-27 Nippon Shinyaku Co Ltd 増殖性糸球体腎炎の予防・治療用薬物のスクリーニング方法
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
AU2003301991A1 (en) * 2002-11-13 2004-06-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 5 (edg5)
AU2003224132A1 (en) 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
JPWO2011087051A1 (ja) * 2010-01-14 2013-05-20 国立大学法人金沢大学 Ｓ１ｐ２受容体アンタゴニストを含む粥状動脈硬化治療薬
KR20130005086A (ko) * 2011-07-05 2013-01-15 한국과학기술연구원 대장암 진단용 단백질 마커 피불린-4 및 이에 대한 항체를 포함하는 대장암 진단 키트

Similar Documents

Publication Publication Date Title
JP2016521114A5 (enExample)
PH12021550307A1 (en) T Cell Receptor Constructs And Uses Thereof
LT4303583T (lt) Csf1r inhibitoriai, skirti panaudoti gydant tenosinovinius gigantinių ląstelių navikus
JP2018529698A5 (enExample)
WO2018132739A3 (en) T cell receptors that bind to ny-eso-1 and methods of use thereof
EA201290027A1 (ru) Ацилированные аналоги глюкагона
BR112013008364A2 (pt) filtros de fumaça para dispositivos de fumar com massas porosas tendo uma carga de partícula de carbono e uma queda de pressão encapsulada
UA117103C2 (uk) Сполука, яка має активність агоніста глюкагону
NZ727701A (en) Platinum compounds, compositions, and uses thereof
EP4324845A3 (en) Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure
MX2017011486A (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
NZ727295A (en) Treatment of immune-related and inflammatory diseases
WO2018104909A3 (en) Dna methylation profiling for t-cell immunotherapy
JP2015509489A5 (enExample)
EA201290837A1 (ru) Лечение волчаночного нефрита с применением лаквинимода
IN2012DN06588A (enExample)
JP2014527400A5 (enExample)
GB201207585D0 (en) An electrode and use thereof
WO2014179424A3 (en) Lipidomic biomarkers
HUE066876T2 (hu) Vízellátó résszel ellátott elektródaszárító berendezés, és eljárás elektródának az elektródaszárító berendezéssel történõ szárítására
WO2015158890A3 (en) Pancreatic cancer therapy and diagnosis
HUE071384T2 (hu) Szénanyag, annak alkalmazása akkumulátorokban, eljárás az anyag elõállítására és az azt tartalmazó elektróda
MX2018013812A (es) Compuestos moduladores del receptor adrenérgico y sus métodos de uso.
ES2640752T3 (es) Agonistas del receptor 5-HT4 para el tratamiento de la demencia
MX2018003697A (es) Metodos para el tratamiento de linfoma difuso de linfocitos b grandes y uso de biomarcadores como predictores de receptividad a farmacos.